All In Biotech

Drug Trial Radar · NCT06890884

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 594 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

594

Planned (sponsor's estimate)

Start

Apr 11, 2025

Primary completion

Dec 13, 2027

Study completion Dec 16, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Mar 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing. The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.

Conditions

  • Lymphoma, Large B-Cell, Diffuse

Interventions

  • Zilovertamab vedotinBiological

    IV infusion

  • RituximabBiological

    IV infusion

  • CyclophosphamideDrug

    IV infusion

  • DoxorubicinDrug

    IV infusion

  • Rituximab BiosimilarBiological

    IV infusion

  • PrednisoneDrug

    Oral administration or IV infusion

  • PrednisoloneDrug

    Oral administration or IV infusion

  • Polatuzumab vedotinBiological

    IV infusion

  • Rescue MedicationDrug

    Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medication is Granulocyte Colony-Stimulating Factor (G-CSF).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Response Rate (CRR) at End of Treatment (EOT) per Lugano Response CriteriaTime frame: Up to approximately 31 months

Locations

148 sites in 9 countries. Site status is shown where the registry gives one.

  • Infirmary Cancer Care ( Site 0157)

    Mobile, Alabama · Recruiting

  • Ironwood Cancer & Research Centers ( Site 0204)

    Chandler, Arizona · Recruiting

  • Palo Verde Cancer Specialists ( Site 0105)

    Glendale, Arizona · Recruiting

  • City of Hope - Phoenix ( Site 0202)

    Goodyear, Arizona · Recruiting

  • Genesis Cancer and Blood Institute ( Site 0193)

    Hot Springs, Arkansas · Recruiting

  • Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0135)

    Burbank, California · Recruiting

  • City of Hope Comprehensive Cancer Center ( Site 0191)

    Duarte, California · Recruiting

  • Moores Cancer Center ( Site 0187)

    La Jolla, California · Recruiting

  • Bass Medical Group ( Site 0123)

    Walnut Creek, California · Recruiting

  • Rocky Mountain Cancer Centers (RMCC) ( Site 8001)

    Aurora, Colorado · Recruiting

  • Colorado West Healthcare System-Grand Valley Oncology ( Site 0165)

    Grand Junction, Colorado · Recruiting

  • Medical Oncology Hematology Consultants (MOHC) ( Site 8007)

    Newark, Delaware · Recruiting

  • Georgetown University Medical Center ( Site 0117)

    Washington D.C., District of Columbia · Recruiting

  • Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0130)

    Boca Raton, Florida · Recruiting

  • Baptist MD Anderson Cancer Center ( Site 0176)

    Jacksonville, Florida · Recruiting

  • Mount Sinai Braman Comprehensive Cancer Center ( Site 0140)

    Miami Beach, Florida · Recruiting

  • Mid Florida Hematology and Oncology Center ( Site 0152)

    Orange City, Florida · Recruiting

  • Beacon Cancer Care ( Site 0142)

    Post Falls, Idaho · Recruiting

  • University of Chicago Medical Center ( Site 0126)

    Chicago, Illinois · Recruiting

  • Illinois Cancer Care ( Site 7005)

    Peoria, Illinois · Recruiting

  • University of Iowa-Holden Comprehensive Cancer Center ( Site 0139)

    Iowa City, Iowa · Recruiting

  • Mission Blood & Cancer Care ( Site 0114)

    Waukee, Iowa · Recruiting

  • Saint Elizabeth Medical Center Edgewood ( Site 0141)

    Edgewood, Kentucky · Recruiting

  • Baptist Health Hardin ( Site 0154)

    Elizabethtown, Kentucky · Recruiting

  • Baptist Health Lexington ( Site 0127)

    Lexington, Kentucky · Recruiting

  • Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0185)

    Louisville, Kentucky · Recruiting

  • Our Lady of the Lake Physician Group-Medical Oncology ( Site 0180)

    Baton Rouge, Louisiana · Recruiting

  • Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0209)

    Monroe, Louisiana · Recruiting

  • Ochsner Clinic Foundation ( Site 0189)

    New Orleans, Louisiana · Recruiting

  • Louisiana State University Health Sciences Shreveport ( Site 0195)

    Shreveport, Louisiana · Recruiting

  • Beth Israel Deaconess Medical Center ( Site 0161)

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute ( Site 0111)

    Boston, Massachusetts · Recruiting

  • Minnesota Oncology Hematology (MNO) ( Site 8004)

    Burnsville, Minnesota · Active not recruiting

  • Bozeman Health Deaconess Hospital ( Site 0183)

    Bozeman, Montana · Recruiting

  • NHO Revive Research Institute, LLC ( Site 0121)

    Lincoln, Nebraska · Recruiting

  • University Of Nebraska Medical Center ( Site 0110)

    Omaha, Nebraska · Recruiting

  • Atlantic Health Morristown Medical Center ( Site 0163)

    Morristown, New Jersey · Recruiting

  • Valley Health Systems - Ridgewood Campus ( Site 0125)

    Paramus, New Jersey · Recruiting

  • Erie County Medical Center ( Site 0175)

    Buffalo, New York · Completed

  • Roswell Park Cancer Institute ( Site 0192)

    Buffalo, New York · Recruiting

Showing 40 of 148 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.